Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.

PloS one - 1 Jan 2013

Kharitonenkov Alexei, Beals John M, Micanovic Radmila, Strifler Beth A, Rathnachalam Radhakrishnan, Wroblewski Victor J, Li Shun, Koester Anja, Ford Amy M, Coskun Tamer, Dunbar James D, Cheng Christine C, Frye Christopher C, Bumol Thomas F, Moller David E

Abstract excerpt

Fibroblast growth factor 21 is a novel hormonal regulator with the potential to treat a broad variety of metabolic abnormalities, such as type 2 diabetes, obesity, hepatic steatosis, and cardiovascular disease. Human recombinant wild type FGF21 (FGF21) has been shown to ameliorate metabolic disorders in rodents and non-human primates. However, development of FGF21 as a drug is challenging and requires...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibroblast Growth Factors

Share to Hep G2 Cells

Share to Klotho Proteins

Share to Pichia

Share to Protein Stability

Share to Temperature

Source

Open in PubMed Open full text

Identifiers

PMID: 23536797
DOI: 10.1371/journal.pone.0058575
PMCID: PMC3594191

Genes

FGF21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.PMID 23536797Read ↗

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.Semantic proximity Read ↗

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).Semantic proximity Read ↗

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.Semantic proximity Read ↗

[Optimization and characterization of a novel FGF21 mutant].Semantic proximity Read ↗

Temperature-responsive structural reversibility of FGF21 and structure-based design of its variant with enhanced potencySemantic proximity Read ↗

Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice.Semantic proximity Read ↗

Different roles of N- and C- termini in the functional activity of FGF21.Semantic proximity Read ↗

Fibroblast growth factor 21: update on genetics and molecular biology.Semantic proximity Read ↗

Genetic evidence supporting fibroblast growth factor 21 signalling as a pharmacological target for cardiometabolic outcomes and Alzheimer's diseaseSemantic proximity Read ↗

Genetic Evidence Supporting Fibroblast Growth Factor 21 Signalling as a Pharmacological Target for Cardiometabolic Outcomes and Alzheimer's Disease.Semantic proximity Read ↗

Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans.Semantic proximity Read ↗

Flexible regions govern promiscuous binding of IL ‐24 to receptors IL ‐20R1 and IL ‐22R1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.